(a) from 1 January 1991 in respect of an application for a reimbursement by a designated corporation within the meaning of section 2 of the Indians and Bands on certain Indian Settlements Remission Order, made by Order in Council P.C. 1992-1052 dated 14 May 1992, as amended by Order in Council P.C. 1994-2096 dated 14 December 1994, under the Financial Administration Act (Revised Statutes of Canada, 1985, c. F-11);

(b) from 1 July 1992 in respect of an application for a reimbursement by an Indian.

4. This Regulation comes into force on the date of its publication in the *Gazette officielle du Québec*.

1943

Gouvernement du Québec

O.C. 1709-97, 17 December 1997

An Act respecting prescription drug insurance and amending various legislative provisions
(1996, c. 32)

Basic prescription drug insurance plan — Amendments

Regulation to amend the Regulation respecting the basic prescription drug insurance plan

WHEREAS under subparagraph 3 of the first paragraph of section 78 of the Act respecting prescription drug insurance and amending various legislative provisions (1996, c. 32), the Government may, after consulting the Régie de l'assurance-maladie du Québec, make regulations to determine the cases, conditions and therapeutic indications in and for which the cost of certain medications included in the list drawn up by the Minister in accordance with section 60 of the Act is covered by the basic prescription drug insurance plan; the conditions may vary according to whether the coverage is provided by the Board or under a group insurance contract or an employee benefit plan;

WHEREAS under section 79 of the Act, such a regulation is not subject to the requirements concerning publication and date of coming into force contained in sections 8 and 17 of the Regulations Act (R.S.Q., c. R-18.1);

WHEREAS by Order in Council 1519-96 dated 4 December 1996, the Government made the Regulation respecting the basic prescription drug insurance plan;

WHEREAS it is expedient to amend the Regulation;

WHEREAS, in accordance with section 78 of the Act respecting prescription drug insurance and amending various legislative provisions, the Régie de l'assurance-maladie du Québec has been consulted on those amendments;

IT IS ORDERED, therefore, upon the recommendation of the Minister of Health and Social Services:

THAT the Regulation to amend the Regulation respecting the basic prescription drug insurance plan, attached to this Order in Council, be made.

MICHEL CARPENTIER,
Clerk of the Conseil exécutif

Regulation to amend the Regulation respecting the basic prescription drug insurance plan*

An Act respecting prescription drug insurance and amending various legislative provisions
(1996, c. 32, s. 78, 1st par., subpar. 3)

1. The Regulation respecting the basic prescription drug insurance plan is amended in the second paragraph of section 2.1

(1) by striking out subparagraph 3;

(2) by inserting the following paragraph after paragraph *b* of subparagraph 11:

"*(c)* as a phosphate binder in persons suffering from severe renal failure and unable to take tablets;";

(3) by inserting the following after subparagraph 24:

"(24.1) DOLASETRON MESYLATE, tab.:

(a) during the first day of a highly emetic chemotherapy or radiotherapy treatment;

(b) during chemotherapy or radiotherapy undergone by persons for whom the conventional antiemetic therapy is ineffective or poorly tolerated;";

(4) by substituting the following for subparagraph 30:

* The Regulation respecting the basic prescription drug insurance plan, made by Order in Council 1519-96 dated 4 December 1996 (1996, *G.O.* 2, 4941), has most recently been amended by the Regulation made by Order in Council 1217-97 dated 17 September 1997 (1997, *G.O.* 2, 4996). For earlier amendments, see the Tableau des modifications et Index sommaire, Éditeur officiel du Québec, 1997, updated to 1 September 1997.

"(30) FAMCICLOVIR:

(a) in immunocompetent persons:

for early treatment of zona, that is, within 48 to 72 hours following the appearance of lesions;

for curative treatment of severe infectious episodes of recurrent genital herpes;

for suppressive treatment of recurrent genital herpes, that is, 6 episodes or more per year;

(b) in immunocompromised persons, for curative and preventive treatment of severe herpes virus infections where acyclovir is ineffective or poorly tolerated;";

(5) by substituting the number "12" for the number "9" in paragraph *a* of subparagraph 34;

(6) by striking out "maximum initial duration of authorization: 3 months" in paragraph *b* of subparagraph 34;

(7) by substituting "The results of re-exposure to milk must be supplied in order for use to continue;"; for that which follows the word "problems" in paragraph *c* of subparagraph 34;

(8) by striking out "maximum initial duration of authorization: 3 months" in subparagraphs 35 and 41;

(9) by striking out "maximum initial duration of authorization: 3 months" in subparagraphs 38, 39 and 40;

(10) by substituting the following for subparagraph 42:

"(42) GANCICLOVIR, caps.:

(a) for maintenance treatment of cytomegalovirus (CMV) retinitis in immunocompromised persons;

(b) for prevention of cytomegalovirus infections in persons having undergone a liver transplant;";

(11) by inserting the following after subparagraph 42:

"(42.1) GLATIRAMER ACETATE:

for treatment of persons suffering from cyclic remitting multiple sclerosis who are capable of walking, even if they require assistance, and who have had 2 or more episodes of the disease within the last 2 years.

The physician must provide, at the beginning of treatment and with each subsequent request, the following information: number of episodes per year, result on EDSS scale, and adjuvant treatments.

The maximum initial duration of authorization is 6 months. When submitting subsequent requests, the physician must provide evidence of a beneficial effect (absence of deterioration);";

(12) by inserting the following after subparagraph 52:

"(52.1) LATANOPROST:

(a) for adjuvant treatment of glaucoma where treatment with a beta-blocker and dorzolamide produces insufficient control of ocular tension;

(b) for adjuvant treatment of glaucoma where treatment with a beta-blocker produces insufficient control of ocular tension and where dorzolamide is not tolerated or is contraindicated;";

(13) by striking out "oral sol." in subparagraphs 53 and 54;

(14) by substituting "graves ou d'ulcères cutanés sévères" for "ou d'ulcères cutanés graves" in the French text of subparagraph 76; and

(15) by substituting the following for subparagraph 88:

"(88) VALACYCLOVIR HYDROCHLORIDE:

(a) in immunocompetent persons:

for early treatment of zona, that is, within 48 to 72 hours following the appearance of lesions;

for curative treatment of severe infectious episodes of recurrent genital herpes;

for suppressive treatment of recurrent genital herpes, that is, 6 episodes or more per year;

(b) in immunocompromised persons, for curative and preventive treatment of severe herpes virus infections where acyclovir is ineffective or poorly tolerated.".

2. This Regulation comes into force on 1 January 1998.

1944